Brief: SynAct Receives Notice Of Allowance For Grant Of U.S. Patent
23/04/2025 07:05
April 23 (Reuters) - SynAct Pharma AB SYNACT.ST: SYNACT RECEIVES NOTICE OF ALLOWANCE FOR GRANT OF US PATENT COVERING RESOMELAGON (AP1189) COMBINATION THERAPY US PATENT, WHEN ISSUED, CAN BE ENFORCED AT LEAST UNTIL 2040 Source text: ID:nMFN5T4Lzd Further company coverage: SYNACT.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on SynAct Pharma AB
See all newsSweden's SynAct Pharma Q3 net loss narrows as expenses fall
Brief: SynAct Pharma Q3 Net Income SEK -32.177 Million
Brief: SynAct Pharma Signs First Commercial Partnership For Resomelagon
Brief: WHO Names Resomelagon Among Key Dengue Drug Candidates
Brief: SynAct Pharma Says Advance Analysis Supports Phase 3 Development